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Abstract
Background: Inflammatory breast cancer (IBC) is a very aggressive and lethal subtype of breast cancer that accounts
for about 4 % of all breast cancers diagnosed in the United States. Despite the efforts of several investigators to identify
the molecular factors driving the aggressive phenotype of IBC, a great deal is still unknown about the molecular
underpinnings of the disease. In the present study, we investigated the role of interferon-induced transmembrane
protein 1 (IFITM1), a well-known interferon-stimulated gene (ISG), in promoting the aggressiveness of SUM149
IBC cells.
Methods: Western blot and real-time polymerase chain reaction analyses were performed to assess the
protein and messenger RNA (mRNA) levels of IFITM1 and other ISGs in three IBC cell lines: SUM149, MDA-IBC-3, and
SUM190. IFITM1 expression and cellular localization were assessed by using immunofluorescence, while the
tumorigenic potential was assessed by performing cell migration, invasion, and colony formation assays. Small
interfering RNA and short hairpin RNA knockdowns, enzyme-linked immunosorbent assays, and luciferase assays were
performed to determine the functional significance of IFITM1 and signal transducers and activators of transcription 1
and 2 (STAT1/2) in SUM149 cells.
Results: We found that IFITM1 was constitutively overexpressed at the mRNA and protein levels in triple-negative
SUM149 IBC cells, but that it was not expressed in SUM190 and MDA-IBC-3 IBC cells, and that suppression of IFITM1 or
blockade of the IFNα signaling pathway significantly reduced the aggressive phenotype of SUM149 cells. Additionally,
we found that knockdown of STAT2 abolished IFITM1 expression and IFITM1 promoter activity in SUM149 cells and
that loss of STAT2 significantly inhibited the ability of SUM149 cells to proliferate, migrate, invade, and form 2-D
colonies. Notably, we found that STAT2-mediated activation of IFITM1 was particularly dependent on the chromatin
remodeler brahma-related gene 1 (BRG1), which was significantly elevated in SUM149 cells compared with SUM190
and MDA-IBC-3 cells.
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Conclusions: These findings indicate that overexpression of IFITM1 enhances the aggressive phenotype of
triple-negative SUM149 IBC cells and that this effect is dependent on STAT2/BRG1 interaction. Further studies are
necessary to explore the potential of IFITM1 as a novel therapeutic target and prognostic marker for some subtypes of
IBCs.
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Background
Inflammatory breast cancer (IBC) is one of the most ag-
gressive and lethal subtypes of human breast cancer, ac-
counting for about 4 % of all breast cancer cases diagnosed
in the United States. A recent study published by Fouad et
al. [1] showed that the 5-year overall survival for patients
diagnosed with stage IV IBC is significantly lower than that
of patients diagnosed with stage IV non-IBC, emphasizing
the lethality of IBC [2–5]. In the last decade, remarkable
progress has been made toward genomic profiling of IBC,
leading to identification of molecular alterations commonly
found in these tumors. The most notable alterations that
have been reported include lack of estrogen and progester-
one receptors (ER−/PR−); overexpression of epidermal
growth factor receptor, ERBB2/human epidermal growth
factor receptor 2 (HER2), E-cadherin, eIF4GI, chemokines,
and chemokine receptors; dysfunction of mucin 1; high
proliferation; tumor protein 53 mutations; and elevated
angiogenesis [6]. Despite these efforts, however, there is
still a great deal that is not known about the biology of IBC
or the factors that drive its aggressive phenotype.
A recent study by the international IBC consortium
reported that the interferon alpha (IFNα) signaling path-
way was significantly upregulated in IBC [7]. Interferons
(IFNs) are cytokines that affect biological responses
through the Janus kinase/signal transducer and activator
of transcription (JAK-STAT) signaling pathway. This path-
way involves IFNs, which, acting as ligands, bind their cor-
responding receptors [interferon (alpha, beta and omega)
receptor (IFNAR)/interferon gamma receptor], resulting
in the phosphorylation and activation of STAT1 and
STAT2 and subsequent transcription of interferon-
stimulated genes (ISGs), which include STAT1, STAT2,
phospholipid scramblase 1 (PLSCR1), interferon-induced
transmembrane protein 1 (IFITM1), interferon-inducible
protein 27 (IFI27), interferon-induced protein with tetra-
tricopeptide repeats 1 (IFIT1), and many others [8]. The
transcription of these ISGs requires the remodeling of
their promoter regions to increase accessibility to tran-
scription factors. Brahma-related gene 1 (BRG1), which is
the adenosine triphosphate (ATP) subunit of the brahma-
associated factor (BAF) complex, is responsible for the
remodeling of the promoter region of many ISGs and
is recruited to its site of action by STAT2 [9]. Several
studies have suggested that altered type I IFNα/IFNβ
signaling, resulting in increased expression of ISGs,
might play a role in tumorigenesis and contribute to
poor patient prognosis [10–13]. Indeed, increased expres-
sion of IFITM1, a well-known ISG, has been shown to
correlate with disease progression, resistance to endocrine
therapy and chemotherapy, and worse overall prognosis in
patients with gastrointestinal, colorectal, and breast can-
cers [14, 15].
IFITM1 is a member of the IFITM protein family
whose expression is strongly induced by type I IFNs
[16]. It was initially identified as a leukocyte antigen that
is part of a membrane complex involved in the transduc-
tion of antiproliferative and homotypic cell adhesion sig-
nals in lymphocytes [17]. Most recently, however, there
has been evidence to suggest that IFITM1 might also
play a role in tumorigenesis. IFITM1 has been shown to
be overexpressed in several types of cancers, including
colorectal, gastrointestinal, head and neck, and breast
cancers, and its overexpression positively correlates with
tumor progression and increased invasiveness [14, 18–21].
We hypothesized that hyperactivation of the IFNα sig-
naling pathway drives IFITM1 overexpression, which
enhances the aggressive phenotype of IBC cells.
In this study, we measured IFITM1 expression in three
IBC cell lines—SUM149, SUM190, and MDA-IBC-
3—and in a non-IBC breast cancer cell line, MCF-7. We
found that IFITM1 was highly expressed in SUM149
cells, which are ER−/PR−/HER2−, but not expressed in
HER2-overexpressing SUM190 and MDA-IBC-3 cells or
ER+/PR+ MCF-7 cells. We also found that IFITM1 over-
expression promoted—whereas its knockdown inhibi-
ted—proliferation, migration, invasion, and tumorigenicity
in SUM149 cells. Additionally, we determined that block-
ade of IFNα signaling using a neutralizing antibody against
its receptor, IFNAR1/2, or knockdown of STAT2 and the
chromatin remodeling protein BRG1, dramatically re-
duced IFITM1 expression and the tumorigenic potential
of SUM149 cells. These findings suggest a critical role for
IFNα signaling and STAT2-mediated activation of IFITM1
in promoting the aggressiveness of triple-negative
SUM149 IBC cells; however, additional studies need to be
performed in other triple-negative inflammatory breast
cancer (TNIBC) cell lines as well as in IBC tumors to val-
idate the biological and clinical significance of these find-
ings in IBC.
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Methods
Reagents
Ham’s F-12 (1×) nutrient mixture (catalogue number
11765-054), RPMI 1640 medium (catalogue number
11875-093), fetal bovine serum (FBS; catalogue number
16000-044), antibiotic/antimycotic solution (containing
10,000 U/ml penicillin, 10 mg/ml streptomycin, and 25 μg/
ml Fungizone®), minimum essential medium nonessential
amino acids, L-glutamine, and TrypLE (containing trypsin
and ethylenediaminetetraacetic acid) were obtained from
Life Technologies (Grand Island, NY, USA). Insulin (bovine
pancreas), anti-β-actin, and hydrocortisone were obtained
from Sigma-Aldrich (St. Louis, MO, USA). Anti-IFITM1,
anti-STAT1, anti-STAT2, anti-BRG1, anti-p-STAT2 (Tyr690),
anti-interferon regulatory factor (IRF)-7, anti-IFNα, anti-p21,
anti-cyclin D1, and anti-cyclin E antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and rabbit polyclonal and mouse monoclonal sec-
ondary antibodies and anti-p-STAT1 (Tyr701) were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). IFITM1 promoter constructs were kindly provided
by Dr. Yeon-Su Lee from the Cancer Genomics Branch,
National Cancer Center, Goyang-si, South Korea.
Cell lines and culture conditions
Experiments were performed using the IBC cell lines
SUM149, SUM190, and MDA-IBC-3 and a non-IBC breast
cancer cell line, MCF-7. SUM149 and SUM190 cells were
obtained from Dr. Massimo Cristofanilli (Northwestern
University, Chicago, IL, USA), who purchased them from
Asterand Bioscience (Detroit, MI, USA). MDA-IBC-3 cells
were developed by Dr. Wendy Woodward (The University
of Texas MD Anderson Cancer Center, Houston, TX,
USA) and were provided to us by Dr. Massimo Cristofanilli
(Northwestern University, Chicago IL). The IBC cells were
maintained in Ham’s F-12 nutrient mixture supplemented
with 10 % FBS, 5 μg/ml insulin, 1 μg/ml hydrocortisone,
and 100 U/ml antibiotic-antimycotic. The ER+, hormone-
dependent human breast cancer cell line MCF-7 was ob-
tained from the American Type Culture Collection (Ma-
nassas, VA, USA) and was maintained in full serum
medium composed of RPMI 1640 medium, 10 % FBS,
2 mM glutamine, penicillin at 100 U/ml, streptomycin at
100 μg/ml, 1× nonessential amino acids (Life Technolo-
gies), and bovine insulin at 6 ng/ml (Sigma-Aldrich, St
Louis, MO). The cells were passaged twice weekly, with
media changed every other day, and they were cultured at
37 °C in a 5 % CO2 atmosphere. The cells were plated and
incubated overnight for attachment before the treatment
protocols were begun.
Anchorage-independent growth
Anchorage-independent growth was performed in soft
agar for SUM149 and SUM190 cells. The experiments
were performed in 6-well plates as per the protocol pub-
lished by Debeb et al. [22]. Briefly, the base layer was
made of 2 ml of medium containing 1 % FBS and 0.5 %
agarose (A9539-100G; Sigma-Aldrich). A quantity of 5 ×
104 cells was layered onto the base in 2 ml of medium
containing 1 % FBS and 0.35 % agarose. The plates were
briefly cooled at 4 °C so that agarose could solidify be-
fore the growth medium was added, and the plates were
kept in the 37 °C incubator for 21 days. Images of the
colonies were captured using the ChemiDoc™ XRS
System equipped with Image Lab™ software (Bio-Rad
Laboratories, Hercules, CA, USA), and using a phase-
contrast microscope equipped with an Olympus cam-
era (Olympus America, Center Valley, PA, USA).
2-D colony formation
SUM149 cells were plated at low density in 6-well plates
and cultured for 7 days, with media changed every other
day. At the end of the 7 days, the colonies were stained
with 5 % crystal violet for 5 minutes and then washed.
The images of the colonies were captured using the
ChemiDoc™ XRS System equipped with Image Lab™
software.
Wound-healing assay
SUM149 and SUM190 cells were seeded at a density of
3.0 × 105 cells per well in 6-well culture plates overnight
so that the cells would attach. A single wound was made
on the plates for each cell line by scratching the attached
cells using a 200-μl sterile pipette tip. The plates were
washed with complete medium to remove cellular debris
from the scraped surface. The images of the cells were
taken immediately and after 24, 48, and 72 h using a
phase-contrast microscope.
Cell invasion assay
Cell invasion measurements were performed using the
Chemicon 24-well QCM ECMatrix Cell Invasion Assay
(ECM 554; EMD Millipore, Billerica, MA, USA) accord-
ing to the manufacturer’s protocol. Briefly, IBC cells
(1 × 105) in 250 μl of serum-free medium were added to
each insert, and 500 μl of media with or without a
chemoattractant (10 % FBS) was added to the lower
chamber. The plates were returned to the incubator at
37 °C in a 5 % CO2 atmosphere for 48 h. The media with
noninvading cells were removed from the inserts, and
the inserts were placed in cell detachment medium and
incubated for 30 minutes at 37 °C to dislodge the in-
vaded cells. The invaded cells were lysed in the presence
of Molecular Probes CyQUANT GR Dye (Life Tech-
nologies, Eugene, OR, USA) for 15 minutes at room
temperature, and the fluorescence of 200-μl aliquots in
96-well plates was measured using a fluorescence plate
reader with a 480/520-nm filter set. For a second set of
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inserts, the migrated cells were stained with crystal
violet and the images were captured with a phase-
contrast microscope equipped with an Olympus
camera.
MTT assay
Proliferation of IBC cells was determined by using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay. SUM149 and SUM190 cells were
seeded onto 24-well plates at a density of 2.5 × 104 cells
per well in cell culture media and incubated overnight
for attachment, followed by treatment protocols. A 50-μl
MTT solution (5 mg/ml) was added to each well at a
final concentration of 500 μg/ml, and the mixture was
further incubated for 3 h at 37 °C. A quantity of 500 μl
of the solubilizing solution (dimethyl sulfoxide/ethanol
at 1:1 vol/vol) was added to each well and shaken to dis-
solve the crystals. The absorbance was read with a VMax
microplate reader (Molecular Devices, Sunnyvale, CA,
USA) at 570 nM, and the relative cell proliferation was
expressed as a percentage of the control.
Western blotting
The cells were detached using a cell scraper and pelleted
in 1.5-ml microcentrifuge tubes, then lysed with cell lysis
buffer [150 mM NaCl, 1.0 % IGEPAL® CA-630 (Sigma-
Aldrich), 0.5 % sodium deoxycholate, 0.1 % sodium do-
decyl sulfate (SDS), 50 mM Tris, pH 8.0; Thermo Fisher
Radioimmunoprecipitation Assay (RIPA) Lysis and Ex-
traction Buffer, catalogue number 89901, Pierce Biotech-
nology/Thermo Fisher Scientific, Rockford, IL, USA]
containing 1 % protease inhibitor and phosphatase inhibi-
tor cocktail. The protein concentration was determined
using a Bio-Rad protein assay (Bio-Rad Laboratories). Pro-
teins (30 μg) from each sample were separated by 4-12 %
SDS–polyacrylamide gel electrophoresis and electrically
transferred to a polyvinylidene difluoride membrane (Bio-
Rad Laboratories). The membranes were blocked in 5 %
nonfat milk in Tris-buffered saline and Tween 20 (TBS-T)
for 1 h and then incubated with primary antibodies (Santa
Cruz Biotechnology) at 4 °C overnight. The membranes
were washed three times for 10 minutes in TBS-T and in-
cubated with corresponding secondary antibodies (Cell
Signaling Technology) conjugated to horseradish peroxid-
ase anti-rabbit (or anti-mouse) immunoglobulin G (IgG)
in 5 % nonfat milk in TBS-T for 1 h at room temperature,
followed by three washes for 10 minutes. Immunoreactiv-
ity was detected by enhanced chemiluminescence
Western blotting detection reagents (Amersham ECL
Plus; GE Healthcare Life Sciences, Piscataway, NJ, USA).
The Western blot quantitation was performed using
ImageJ software (http://rsb.info.nih.gov/ij/download.html;
National Institutes of Health, Bethesda, MD, USA).
Small interfering RNA transfection
SUM149 cells were transfected with pooled small inter-
fering RNAs (siRNAs) targeting IFITM1, STAT1,
STAT2, BRG1, IFNα2, and IRF7. All of the pooled siR-
NAs contained a mixture of three target-specific 20- to
25-nt siRNAs. For IFITM1 knockdown, the individual
siRNAs used were siRNA 1 (sc-44549A), siRNA 2
(sc-44549B), and siRNA 3 (sc-44549). For STAT1 and
STAT2 knockdown, both individual and pooled siRNAs
were used. The individual siRNAs for STAT1 were siRNA
1 (sc-44123A), siRNA 2 (sc-44123B), and siRNA 3 (sc-
44123), and the individual siRNAs for STAT2 were siRNA
1 (sc-29492A), siRNA 2 (sc-29492B), and siRNA 3 (sc-
29492). siBRG1 (sc-29827), siIRF7 (sc-38011), small inter-
fering interferon α2 (siIFNα2; sc-63324), and scrambled
RNA (siCon; sc-37007) were purchased from Santa Cruz
Biotechnology. The transfection reagent used was Lipofec-
tamine 2000™ from Life Technologies (Carlsbad, CA,
USA). IBC cells were seeded overnight and then trans-
fected at a density of 50–60 % confluence with 60–100
nM of targeted siRNAs or siCon. Transfected cells were
maintained in culture for 24–72 h before being harvested
and further analyzed. We should note that the knockdown
efficiency of individual siRNAs targeting IFITM1, STAT1,
and STAT2 was not statistically significantly different from
that of the pooled siRNAs; hence, the pooled siRNAs were
used for the functional studies.
Short hairpin RNA transfection
SUM149 cells were transfected with IFITM1 short hair-
pin RNA (shRNA) plasmid (h) (shIFITM1; sc-44549-SH)
or control shRNA (shControl; sc-108060) plasmid, both
of which were purchased from Santa Cruz Biotechnol-
ogy. The IFITM1 shRNA plasmid was a pool of three
different shRNA plasmids: SHA, SHB, and SHC. sc-
44549-SHA: hairpin sequence: GATCCCACACTTCTC
AAACCTTCATTCAAG AGATGAAGGTTTGAGAAG
TGTGTTTTT; corresponding siRNA sequences (sc-
44549A): sense: CACACUUCUCAAACCUUCAtt;
antisense: UGAAGGUUUGAGAAGUGUGtt; sc-44549-
SHB: hairpin sequence: GATCCCTGTGACAGTCTAC
CATATTTCAAGAGAATA TGGTAGACTGTCACAGTT
TTT; corresponding siRNA sequences (sc-44549B): sense:
CUGUGACAGUCUACCAUAUtt; antisense: AUAUGGU
AGACUGUCACAGtt; sc-44549-SHC: hairpin sequence:
GATCCCTGTCTACAGTGTCATTCATTCAAGAGATGA
ATGACA CTGTAGACAGTTTTT; corresponding siRNA
sequences (sc-44549C): sense: CUGUCUACAGUGUCA
UUCAtt; antisense: UGAAUGACACUGUAGACAGtt.
SUM149 cells were seeded into 6-well plates, and at 60–
70 % confluence they were transfected with 6–10 μg of
shIFITM1 or shControl plasmid using Lipofectamine
2000™ reagent according to the manufacturer’s instruc-
tions. The transfected cells were incubated for 24–72 h,
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and the knockdown was confirmed by Western blot ana-
lysis and real-time polymerase chain reaction (RT-PCR).
RNA isolation and RT-PCR analysis
Total RNA was isolated from cultured cells using a QIA-
GEN RNeasy Mini Kit Qiagen (catalogue number 74104;
QIAGEN, Valencia, CA, USA) according to the manufac-
turer’s protocol. First-strand complementary DNA (cDNA)
synthesis was performed using 2.5 μg of total RNA using
Invitrogen SuperScript Reverse Transcriptase (Thermo
Fisher Scientific, Carlsbad, CA, USA). cDNA was ampli-
fied in a 25-μl PCR mixture containing 1 μl of deoxynu-
cleotide triphosphates, 1× PCR buffer, 2.5 mM MgCl2, and
1 U of DNA Taq polymerase (Promega, Madison, WI,
USA) with 25 pmol of primers specific for human IFITM1,
which were obtained from Integrated DNA Technologies
(Coralville, IA, USA) (sense: 5′-GGATTTCGGCTTG
TCCCGAG-3′, antisense: 5′-CCATGTGGAAGGGAGG
GCTC-3′), STAT1 (sense: 5′-GGCACCAGAACGAAT
GAGGG-3′, antisense: 5′- CCATCGTGCACATGGTGG
AG-3′), PLSCR1 (sense: 5′-CATTCACCGGGCTCTCT
AC-3′, antisense: 5′-GGCAGCTGGGCAATCTTGCA-3′),
STAT2 (sense: 5′-GCAGCACAAT TTG GGAA-3′, anti-
sense: 5′-ACAGGTGTTTCGAGAACTGGC-3′), IRF9
(sense: 5′-TTCTGTCC CTGGTGTAGAGCCT-3′, anti-
sense: 5′- TTTCAGGACACGATTATCACGG-3′), IRF7
sense: 5′-GAGCCCTTACCTCCCCTGTTAT-3′, antisense:
5′-CCACTGCAGCCCCTCATAG-3′, IFI27 (sense: 5′-
GCCTCTGGCTCTGCCGTAGTT-3′, antisense: 5′-AT
GGAGGACGAGGCGATTCC-3′), IFIT1 (sense: 5′-TCT
CAGAGGAGCCTGGCTAA-3′, antisense: 5′-CCAGAC
TATCCTT GACCTGATGA-3′), OAS1 (sense: 5′-TGA
GGTCCAGGCTCCACGCT-3′, antisense: 5′-GCAGGT
CGGTGCACTCCTCG-3′). The PCR experiment was
performed according to the manufacturer’s protocol for
Applied Biosystems Power SYBR® Green PCR Master Mix
and RT-PCR (PN 4367218; Life Technologies, Carlsbad,
CA, USA) as follows: enzyme activation step: 10-minute
hold at 95 °C for AmpliTaq Gold® enzyme activation,
followed by PCR amplification steps (40 cycles); and de-
naturation step: 15 seconds at 95 °C, annealing/extension
step: 60 seconds at 60 °C. Pumilio RNA-binding family
member 1 (PUM1) was used as the internal control (sense:
5′-TCACCGAGGCCCCTCTGAACCCTA-3′; antisense:
5′-GGCAGTAATCTCCTTCTGCATCC T-3′). The re-
producibility of the quantitative measurements was evalu-
ated by three independent cDNA syntheses and PCR
amplification from each preparation of messenger RNA
(mRNA). The relative mRNA expression level was deter-
mined as a ratio of the signal intensity to that of PUM1.
Cell-cycle analysis
SUM149 cells were seeded at a density of 3.0 × 105 cells
per well in 6-well culture plates overnight so that cells
could attach. The cells were transfected with small inter-
fering IFITM1 or control siRNA for 24 h. At the end of
the transfection period, the cells were harvested by trypsi-
nization and washed once with phosphate-buffered saline
(PBS), pH 7.4. The cells were fixed in 100 % ice-cold etha-
nol for 24 h and stained with 50 μl/ml of 2 mg/ml propi-
dium iodide stock with 10 μl/ml of RNase A and
incubated for 30 minutes at room temperature. The DNA
contents of 5 × 105 cells were determined using a BD LSR
II flow cytometer (BD Biosciences, San Jose, CA, USA).
The flow cytometry data were analyzed using FlowJo soft-
ware (Tree Star, Ashland, OR, USA) to determine the per-
centages of the cells at each phase of the cell cycle. Three
separate experiments were performed in triplicate, and
IFITM1 knockdown was confirmed by Western blot ana-
lysis after each transfection.
Immunofluorescence microscopy
SUM149 and SUM190 IBC cells were plated onto cham-
bered slides and, after overnight incubation for attach-
ment, were treated with or without IFN for a further
24 h. The cells were washed in PBS and fixed with
100 % methanol for 10 minutes, and then washed three
times for 10 minutes each before being permeabilized
with 0.1 % Triton X-100 in PBS for 10 minutes, followed
by three washes for 5 minutes and then blocking with
5 % normal horse serum for 1 h. The cells were then in-
cubated with anti-IFITM1 primary antibody overnight,
after which they were washed three times in PBS for
10 minutes, followed by staining with fluorescein iso-
thiocyanate–conjugated goat anti-mouse IgG secondary
antibody (4 μg/ml) for 1 h. The coverslips were mounted
on glass slides with VECTASHIELD Mounting Medium
(Vector Laboratories, Burlingame, CA, USA) containing
4′,6-diamidino-2-phenylindole for nuclear counterstain-
ing, and samples were incubated at room temperature
for 24 h before being analyzed using a Leica confocal
microscope equipped with Leica Application Suite Ad-
vanced Fluorescence Lite 2.6.0 Build 7266 software
(Leica Biosystems, Buffalo Grove, IL, USA).
Enzyme-linked immunosorbent assay
Human IFNα levels were measured by enzyme-linked
immunosorbent assay (ELISA; PBL Interferon Source;
PBL Assay Science, Piscataway, NJ, USA). A quantity of
5 × 105 SUM149, SUM190, and MCF-7 cells were seeded
into 6-well plates and incubated at 37 °C overnight so
that the cells would attach. The cells were then treated
with 100 U/ml human recombinant IFNα or transfected
with siIRF7 and siIFNα for 48 h. Cells and supernatants
were harvested and kept at −80 °C until analysis. Protein
was extracted by sonication in RIPA buffer supple-
mented with protease and phosphatase inhibitors. Super-
natants and lysates were purified by centrifugation and
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analyzed for the presence of IFNα according to the man-
ufacturer’s instructions.
Interferon α receptor neutralization
SUM149 cells were treated with 5 μg/ml anti-IFNAR1/2
mouse anti-human IFNα/β receptor monoclonal anti-
body (catalogue number MAB1155; EMD Millipore) for
24 h. The cells were harvested using a cell scraper and
then processed for Western blot analysis.
IFITM1 luciferase promoter assay
SUM149 and SUM190 cells were seeded in 24-well tis-
sue culture plates overnight for attachment before trans-
fection. The cells were transfected using Lipofectamine
2000™ transfection reagent according to the manufac-
turer’s recommendations. Four microliters of Lipofecta-
mine 2000™, 0.8 μg of plasmid DNA (pGL3-Basic
[Promega, Madison, WI, USA], pGL3-IFITM1 [−750/
−1], pGL3-IFITM1 [−200/−1]), and 0.01 μg of the pRL-
CMV Renilla (Promega) were diluted individually in
125-μl aliquots of Gibco Opti-MEM Reduced Serum
Medium (Life Technologies). Cells were incubated for
24 h after transfection and treated with IFNα (200 U),
and then the luciferase and Renilla activities were mea-
sured 24 h later using the Promega Dual-Luciferase Re-
porter Assay System according to the manufacturer’s
instructions. To confirm that the luciferase activity of
each construct was caused by IFNα, the activity of each
construct was assayed in the presence and absence of
IFNα. In a separate set of samples, cells were transfected
with the −750/−1 IFITM1 promoter construct for 24 h,
followed by transfection with siSTAT1 and siSTAT2 for
a further 24 h and subsequent determination of pro-
moter activity. Renilla activity was also assayed to
standardize sample transfection efficiencies.
Statistical analysis
At least three separate experiments were performed for
each measurement. All quantitative data were expressed
as mean ± standard deviation. Comparisons between two
groups were analyzed using t tests in Excel 2010 (version
14.0; Microsoft, Redmond, WA, USA), with P values less
than 0.05 considered statistically significant.
Results
IFITM1 is overexpressed in triple-negative SUM149
inflammatory breast cancer cells
To identify the factors contributing to the aggressive
phenotype of IBC cells, we measured the expression of
IFITM1, an ISG linked to tumor progression, in three
IBC cell lines: triple-negative SUM149, HER2-amplified
SUM190 and MDA-IBC-3, and the non-IBC cell line
MCF-7 (ER+). We found that IFITM1 was highly
expressed in SUM149 cells at the protein (Fig. 1a) and
mRNA (Fig. 1b) levels, but that it was not expressed in
SUM190, MDA-IBC-3, and MCF-7 cells (Fig. 1a). Im-
munofluorescence confirmed that IFITM1 was overex-
pressed in SUM149 cells and that it was localized
primarily in the cytoplasmic and plasma membrane re-
gions of the cells (Fig. 1c). We should note that there
are only a few human IBC cell lines (i.e., SUM149,
SUM190, MDA-IBC-3, MARY-X, and FC-IBC-02) avail-
able for studying this complex disease and that these cell
lines have molecular signatures that are distinct from
each other. Overexpression of IFITM1 in the SUM149
cell line alone suggests that it might be an important
marker in these cells.
IFITM1 knockdown inhibits proliferation, colony
formation, and invasion in SUM149 cells
To assess the functional significance of IFITM1 expres-
sion in SUM149 cells, siRNAs and shRNAs were used to
knock down IFITM1. Three different siRNAs (IFITM1-
siRNA1, IFITM1-siRNA2, and IFITM1-siRNA3) and
IFITM1-shRNA were used. Cells were transfected with
the individual siRNAs (siRNA-1 and siRNA-2), the
pooled siRNA (siRNA-3), shRNA (shIFITM1), scrambled
control (siCon), or shRNA control (shCon) for 72 h. We
found that the individual siRNAs and the pooled siRNA
completely reduced IFITM1 expression in SUM149 cells
(Fig. 2a) and that loss of IFITM1 reduced the prolifera-
tion of SUM149 cells by approximately 52–63 % (Fig. 2b).
Cell-cycle analysis revealed that the inhibitory effect of
IFITM1 knockdown in SUM149 cells was due in part to
G1 arrest (Additional file 1: Figure S1A), which was asso-
ciated with downregulation of cyclin D1 and cyclin E
(Additional file 1: Figure S1B). Additionally, IFITM1
knockdown dramatically reduced the ability of SUM149
cells to form 2-D colonies (Fig. 2c, left and right panels),
to grow in an anchorage-independent manner (Fig. 2d,
left and right panels), and to migrate and invade (Fig. 2e,
left and right panels). We also determined that IFITM1
shRNA completely suppressed IFITM1 expression in
SUM149 cells (shown in Fig. 3a), which resulted in in-
hibition of cell proliferation by up to 54 % (Fig. 3b), mi-
gration (Fig. 3c), and 2-D colony formation (Fig. 3d, left
and right panels).
Enhanced IFNα signaling drives IFITM1 overexpression in
SUM149 cells
Type I IFNα/β induce ISGs by binding to their receptors
IFNAR1/2 and activating the canonical JAK-STAT sig-
naling pathway. To determine whether elevated IFNα
signaling is responsible for driving constitutive IFITM1
overexpression in IBC cells, we first measured IFNα
levels in SUM149, SUM190, and non-IBC MCF-7 cells
using ELISA, and we found that IFNα protein level was
significantly higher in the lysates of SUM149 and
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SUM190 IBC cells compared with non-IBC MCF-7 cells
(data not shown). Notably, RT-PCR analysis revealed
that IFNα mRNA level was approximately 53 % higher
in SUM149 cells compared with SUM190 cells (Fig. 4b).
Next, we determined the effect of IFNα suppression in
SUM149 and SUM190 cells by transfecting these cells
with siRNAs targeting either IFNα and/or its transcrip-
tional regulator IRF7. As shown in Fig. 4a (left panel),
siRNA knockdown of IFNα significantly reduced IFNα
level in the supernatant and lysate of SUM149 cells,
whereas knockdown of IRF7, either alone or combined
with siIFNα, significantly reduced IFNα level in the lys-
ate and supernatant of SUM149 cells, but the differences
were not significant in SUM190 cells (Fig. 4a, right
panel). Western blot analysis also confirmed that
knockdown of IFNα and IRF7, either individually or
combined, markedly reduced IFITM1 protein expression
in SUM149 cells (Fig. 4c). STAT1 and STAT2 proteins
were also reduced following IFNα and IRF7 knockdown
(Fig. 4c). Additionally, we found that blockade of the
IFNα receptors IFNAR1/2 with a neutralizing monoclo-
nal antibody (IFNAR-Ab) completely inhibited IFITM1
protein expression in SUM149 cells (Fig. 4d, left and
right panels), and it markedly reduced STAT1 and
STAT2 protein levels in these cells. Together, these find-
ings confirm that constitutive overexpression of IFITM1
in SUM149 cells is driven in part by activation of the
IFNα signaling pathway. Notably, we also performed
comparative genomic hybridization (CGH) analysis to
assess DNA copy number changes for IFITM1 and other
A B
C
Fig. 1 Interferon-induced transmembrane protein 1 (IFITM1) protein and messenger RNA (mRNA) expression in breast cancer cells. a IFITM1
protein expression in the triple-negative SUM149 cells, human epidermal growth factor receptor 2–overexpressing SUM190 and MDA-IBC-3 cells,
and non–inflammatory breast cancer (non-IBC) MCF-7 cells. The protein expression was assessed by Western blot analysis, with β-actin used as a
loading control. b IFITM1 mRNA expression in SUM149 and SUM190 cells. The mRNA levels were determined by real-time polymerase chain
reaction, and the fold change for each cell line was calculated against the Pumilio RNA-binding family member 1 (PUM1) internal control gene.
Each value shown is the mean ± standard deviation from three independent experiments. *P < 0.05. c IFITM1 protein expression and localization
profiles of SUM149 and SUM190 IBC cells determined by immunofluorescence. The images of the cells were captured using a Leica confocal
microscope equipped with Leica Application Suite Advanced Fluorescence Lite 2.6.0 Build 7266 software. DAPI 4′,6-diamidino-2-phenylindole






Fig. 2 Effects of small interfering RNA (siRNA) knockdown of interferon-induced transmembrane protein 1 (IFITM1) on proliferation and tumorigenic
potential of SUM149 cells. a Western blot analysis of SUM149 cells showing the protein levels of IFITM1. The IFITM1 gene was knocked down using
three separate siRNAs (siRNA 1, siRNA2, and siRNA 3), and the control samples were transfected with a negative control siRNA (siCon) for 72 h. b Cell
proliferation after 72 h of IFITM1 knockdown with three separate siRNAs. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was
performed to assess cell proliferation. Bars represent mean ± standard deviation (SD). **P < 0.005 for siRNA knockdown compared with siCon. c 2-D
colony formation showing the effects of silencing of IFITM1 in SUM149 cells on the formation of colonies in a 2-D surface. The images of the plates
were captured using the ChemiDoc™ XRS System equipped with Image Lab™ software, then transformed and quantified by using ImageJ software. d
Left panel: Anchorage-independent growth in soft agar showing the effect of IFITM1 knockdown on colony formation in SUM149 cells. The representative
images were captured using a phase-contrast microscope equipped with an Olympus camera (original magnification, ×200). Right panel: The colonies
were imaged using the ChemiDoc™ XRS System and quantified using ImageJ software. e Effect of IFITM1 knockdown on cell invasion and
migration in SUM149 cells as assessed by Transwell Matrigel assay (Corning, Corning, NY, USA). The invaded cells were stained with crystal violet
and imaged. f Quantitation of the number of invaded cells in SUM149 cells. The data presented are mean ± SD of three replicates. *P < 0.05
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components of the IFN signaling pathway in SUM149
cells. CGH data revealed that there was no significant
change in the DNA copy number for IFITM1 in
SUM149 cells; however, there was a 27.5 % gain in copy
number for IFNα and IFNβ (data not shown), which
are the ligands that activate the JAK-STAT signaling
pathway. These findings suggest that overexpression of
IFITM1 in SUM149 cells may be due in part to in-
creased expression of IFNα (observed at the DNA,
mRNA, and protein levels), which activates the JAK-
STAT signaling pathway.
STAT2 is a critical regulator of IFITM1 expression in
SUM149 cells
STAT1 and STAT2 are transcription factors that play a
critical role in regulating type I IFNα/β signaling. To
evaluate the role of STAT1 and STAT2 in the regulation
of IFITM1 in SUM149 cells, siRNAs were used to knock
down their expression. As shown in Fig. 5a (left and
right panels), knockdown of STAT2 completely sup-
pressed IFITM1 expression in SUM149 cells, whereas
knockdown of STAT1 did not significantly reduce




Fig. 3 Effects of short hairpin RNA (shRNA) knockdown of interferon-induced transmembrane protein 1 (shIFITM1) on cell proliferation, migration,
and colony formation in SUM149 cells. a Western blot analysis was used to confirm the shRNA knockdown of IFITM1 in SUM149 cells. b Cell proliferation
was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in SUM149 cells that were transfected with shRNA for 24 h and
maintained in culture for a further 48 h. The assay results showed that the knockdown of IFITM1 reduced cell proliferation by up to 52 % in SUM149
cells compared with the short hairpin control cells (shCon). c Cell migration was assessed by wound-healing assay. d Left panel: 2-D colonies formed by
SUM149 cells with and without shRNA knockdown. Right panel: Quantification of the number of colonies. *P < 0.05
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were observed using two additional siRNAs targeting
STAT1 (siRNA1 and siRNA2) (Additional file 2: Figure
S2A) and STAT2 (siRNA1 and siRNA2) (Additional file
2: Figure S2B). Additionally, knockdown of STAT2 re-
duced cell proliferation (Fig. 5b, upper left and right
panels), colony formation (Fig. 5c, upper left and right
panels), and migration (Fig. 5d, right panel) in SUM149
cells, whereas knockdown of STAT1 did not significantly
alter the aggressive phenotype of these cells (Fig. 5b and




Fig. 4 Regulation of interferon-induced transmembrane protein 1 (IFITM1) by the interferon signaling pathway in SUM149 cells. a Human
interferon α (IFNα) levels were measured in the supernatant and lysates of SUM149 and SUM190 cells after the knockdown of IFNα and interferon
regulatory factor 7 (IRF7) using small interfering RNA (siRNA). Measurements of IFNα were done with an enzyme-linked immunosorbent assay
(PBL Interferon Source; PBL Assay Science, Piscataway, NJ, USA) according to the manufacturer’s instructions. The data presented are mean ± standard
deviation. *P < 0.05 compared with siControl. b IFNα messenger RNA (mRNA) levels in SUM149 and SUM190 IBC cells measured by real-time polymerase
chain reaction. *P < 0.05. c Western blot analysis of IFITM1, signal transducer and activator of transcription 1 (STAT1), and STAT2 protein
expression following the suppression of IRF7 and IFNα in SUM149 cells. d Left panel: Western blot showing the protein levels of IFITM1,
STAT1, and STAT2 after interferon receptor (IFNR)-α/β was neutralized using mouse anti-human IFNR-α/β chain 2 monoclonal antibody (Ab)
in SUM149 cells. Right panel: Quantification of IFITM1 protein expression from the Western blots using ImageJ software. *P < 0.05. PUM1
Pumilio RNA-binding family member 1
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Fig. 5 (See legend on next page.)
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BRG1 is a critical regulator of IFITM1 expression in
SUM149 cells
The IFITM1 promoter region has a nucleosome that re-
quires remodeling to expose the interferon-stimulated
response element (ISRE), IFNγ-activated site (GAS), and
IRF sequences and to enable transcription factor bind-
ing. BRG1, the ATP subunit of the BAF chromatin re-
modeling complex, has been shown to be recruited by
STAT2 to the promoter region of ISGs in the process of
transcription. To assess the role of BRG1 in regulating
IFITM1 expression, siRNA knockdown studies were per-
formed in SUM149 cells, and BRG1 and IFITM1 protein
was measured by Western blot analysis. As shown in
Fig. 6, siRNA knockdown of BRG1 protein in SUM149
cells completely suppressed IFITM1 expression in these
cells. These data suggest that STAT2 and BRG1 are
critical regulators of IFITM1 expression in SUM149
cells with less significant involvement of STAT1 in the
process.
STAT2 regulates IFITM1 promoter activity in SUM149 cells
The promoter region of the IFITM1 gene contains ISRE,
GAS, and IRF DNA sequences (Additional file 3: Figure
S3) that provide binding sites for transcription factors
such as STAT1, STAT2, and IRF9. Figure 7a shows sche-
matic diagrams for the full-length IFITM1 promoter
(−1000/+400), the two IFITM1 deletion constructs
(IFITM1 − 750/−1 and IFITM1 − 200/−1), and the empty
vector (pGL3). A luciferase assay was used to measure
IFITM1 promoter activity in SUM149 and SUM190 cells
following transfection of these cells with either pGL3b
−750/−1 or pGL3b −200/−1. As shown in Fig. 7b, we
found that IFITM1 promoter activity was higher in the
cells transfected with the −750/−1 construct as com-
pared with −200/−1, and in SUM149 cells as compared
with SUM190 cells (data not shown). IFN treatment in-
creased the promoter activity for both constructs signifi-
cantly in SUM149 cells (Fig. 7b). To determine the
functional significance of STAT1 and STAT2 on pro-
moter activity, we knocked down STAT1 and STAT2 in
the cells that were transfected with the −750/−1 con-
struct and measured the luciferase activity in the cells.
We found that IFITM1 promoter activity was signifi-
cantly lower in the STAT2 knockdown cells in SUM149
as compared with STAT1 (Fig. 7c), suggesting that
STAT2 played a critical role in IFITM1 induction in
these cells. STAT2 has been shown to form non–ISG
factor 3 (non-ISGF3) complexes in which its homodi-
mers bind to GAS consensus sequence on the promoters
of a subset of ISGs and induce their transcription. Of
the two constructs, the −750/−1 construct has more
TTA half-sites and TTC half-palindromes compared
with the −200/−1 construct, which may explain why it
had higher luciferase activity. Taken together, these find-
ings suggest that STAT2, not STAT1, plays a dominant
role in regulating IFITM1 transcriptional activation in
SUM149 cells through binding to multiple consensus se-
quences such as ISRE/IRF and GAS.
(See figure on previous page.)
Fig. 5 Effects of signal transducer and activator of transcription 1 (STAT1) andSTAT2 knockdown on interferon-induced transmembrane protein 1
(IFITM1) expression and tumorigenic potential of SUM149 cells. a Left panel: Western blots showing the protein levels of STAT1, STAT2, and IFITM1
after STAT1 and STAT2 genes were knocked down in SUM149 cells using siSTAT1 and siSTAT2. β-Actin was used as a loading control. Left panel:
Quantification of the protein levels of IFITM1 in the siSTAT1, siSTAT2, and siSTAT1/2 samples. IFITM1 levels were quantified using ImageJ software,
were normalized to β-actin, and were expressed relative to siControl. b Upper panel: Western blot of STAT2 knockdown in SUM149 cells and the
effects of the knockdown on cell proliferation. Lower panel: Western blot of STAT1 knockdown in SUM149 cells and the effects of the knockdown
on cell proliferation. c Left panel: Effects of STAT1 and STAT2 knockdown on 2-D colony formation in SUM149 cells. Right panel: Quantification of
the colonies. d Wound-healing assay showing the effects of STAT1 and STAT2 knockdowns on the ability of SUM149 cells to migrate. *P < 0.05
Fig. 6 Effects of brahma-related gene 1 (BRG1) knockdown on interferon-induced transmembrane protein 1 (IFITM1) expression in SUM149 cells.
Left panel: Western blot showing the protein levels of BRG1 and IFITM1 after BRG1 gene was knocked down using siBRG1 for 48 h in SUM149 cells.
β-actin was used as a loading control. Right panel: Quantification of IFITM1 protein levels from the Western blots. *P < 0.05
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Functional integrity of the IFNα signaling pathway in
SUM149 cells
Because IFITM1 was constitutively overexpressed in
SUM149 cells, we next determined whether exogenous
IFNα was capable of activating the IFNα signaling pathway
in these cells. As shown in Fig. 8a, exogenous treatment
with IFNα increased IFITM1 protein expression in both
SUM149 and SUM190 cells within 6–8 h of treatment, with
maximum induction at 24 h; however, basal expression of
IFITM1 was observed in SUM149 cells from time 0 but not
in SUM190 cells until 6 h posttreatment with IFNα. Not-
ably, exogenous IFNα also increased total STAT1 and
STAT2 protein expression in both cell lines, but the induc-
tion of STAT1 and STAT2 by exogenous IFNα was less ro-
bust than that of IFITM1. Interestingly, p-STAT2 (Tyr690)
was induced significantly more in SUM149 than in SUM190
cells 1 h after treatment with IFNα and faded after 5 h. The
higher STAT2 phosphorylation in SUM149 cells further
supports the critical role it plays in IFITM1 overexpression
and partly explains the differences in IFITM1 expression in
the IBC cell lines. Additionally, immunofluorescence data
(Fig. 8b) showed that exogenous addition of IFNα increased
IFITM1 protein expression in both IBC cell lines. Overall,
these results show that type I IFN signaling is constitutively
enhanced in SUM149 cells; however, these cells are still re-
sponsive to exogenous IFNα.
Discussion
IBC is a rare and highly aggressive subtype of breast can-
cer that is not well characterized at the molecular level. In
this study, we report a novel role for the ISG IFITM1 in
promoting the aggressive phenotype of SUM149 IBC cells.
In particular, we show that IFITM1 was constitutively
overexpressed at the mRNA and protein levels in triple-
A
B C
Fig. 7 Interferon-induced transmembrane protein 1 (IFITM1) promoter activity in SUM149 cells. a Schematic diagram of the IFITM1 promoter
showing ATG transcription start site, interferon-stimulated response element (ISRE)/interferon regulatory factor (IRF), interferon gamma-activated
site (GAS), TTA half-sites, and TTC half-palindromes; constructs; pGL3-IFITM1 − 750/−1, pGL3-IFITM1 − 200/−1, and the empty vector (pGL3). b Relative
luciferase activity of the IFITM1 promoter region using the two deletion constructs (−750/−1 and −200/−1), along with interferon treatment in
SUM149 cells. c Effects of signal transducer and activator of transcription 1 (STAT1) and STAT2 knockdown on the IFITM1 promoter activity using
the −750/−1 deletion construct. The luciferase activity was expressed relative to scrambled control RNA (siCon). The data presented are
representative of triplicate experiments and are expressed as mean ± standard deviation. *P < 0.05. RLU stands for Relative Light Units (RLU). It is
a unit that is based on light emitted by the luciferase-catalyzed chemiluminescent reaction
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negative SUM149 cells but was not expressed in HER2-
amplified SUM190 or MDA-IBC-3 IBC cells. We also
found that IFITM1 overexpression promoted—whereas its
knockdown inhibited—proliferation, migration/invasion,
and tumorigenicity in vitro. Furthermore, we demonstrate
that SUM149 cells expressed and secreted elevated levels
of type I IFNα and that blockade of IFNα signaling using a
neutralizing antibody against its receptor, IFNAR1/2, or
Fig. 8 Activation of type I interferon (IFN) signaling pathway by exogenous IFNα in SUM149 and SUM190 cells. a Effects of IFN induction on the
protein levels of IFN-stimulated genes (IFITM1, STAT1, p-STAT1, STAT2, and p-STAT2) in the SUM149 and SUM190 cells. β-Actin was used as a
loading control. b Cellular localization and expression of interferon-induced transmembrane protein 1 (IFITM1) protein in SUM149 and SUM190
cells following IFN induction. Immunofluorescence was used to assess IFITM1 expression and localization in the cells that were induced with IFNα
for 24 h as compared with the control. The images were captured using Leica confocal microscope. DAPI 4′,6-diamidino-2-phenylindole, STAT
signal transducer and activator of transcription
Ogony et al. Breast Cancer Research  (2016) 18:25 Page 14 of 19
knockdown of STAT2, suppressed IFITM1 expression in
SUM149 cells. Loss of IFITM1 expression dramatically re-
duced the ability of these cells to proliferate, migrate, in-
vade, and form colonies in soft agar. We should note that
differential regulation of IFN response genes has been ob-
served in many human malignancies, including leukemia
[21], ovarian cancer [23], gastric cancer [14], lung cancer
[24], colon cancer [25], and breast cancer [26] and that
high expression of ISGs is associated with poor clinical
outcome [14]. However, to our knowledge, this study is
the first to highlight a critical role for the IFNα signaling
pathway and the IFN response gene IFITM1 in enhancing
the aggressive phenotype of triple-negative SUM149 cells.
The fact that IFITM1 was highly expressed in SUM149
cells, which are triple-negative, but was not expressed in
HER2-amplified SUM190 and MDA-IBC-3 cells suggests
that it might be a unique molecular marker of TNIBC and
that it could be a potential therapeutic target in patients
with TNIBC. Approximately 60 % of IBCs are basal-like or
triple-negative, as characterized by the ER−, PR−, and hu-
man epidermal growth factor receptor 2 (HER2)-non-
amplified status [27]. Patients with TNBC have a lower
overall survival rate [28] and very limited therapeutic
options. In contrast, HER2 amplification occurs in ap-
proximately 40 % of IBCs [29, 30], and IBC patients
with HER2-amplified tumors have been shown to re-
spond favorably to anti-HER2 therapies [31].
Over the past 3 decades, IFNs (α, β, γ) have established
a reputation for being immunologic guardians against
disease and as promising antitumor agents [32–35];
however, recent evidence suggests that IFNs may also
promote tumor progression. Indeed, it has been reported
that breast cancer patients whose tumors express high
IFN response genes are 1.7 times more likely to develop
metastasis and to die as a result of the disease as com-
pared with patients whose tumors express low levels of
the IFN response gene signature [36]. Furthermore, in-
creased expression of a subset of ISGs, including
IFITM1, EIF2AK2, STAT1, and IFI27, has been reported
in several types of cancers, and these ISGs have been
shown to promote tumor growth and resistance to
chemotherapy and radiotherapy [11, 37, 38]. Consistent
with these reports, our present study revealed constitu-
tive activation of the IFNα signaling pathway in IBC
cells, which was strongly associated with IFITM1 over-
expression. Notably, blockade of IFNα signaling using a
neutralizing antibody against the type I IFN receptor,
IFNAR1/2, completely suppressed IFITM1 expression,
and it markedly reduced the tumorigenic potential of
SUM149 cells in vitro. While the mechanism by which
IFITM1 overexpression enhances the aggressiveness of
SUM149 cells is not known, we should note that Ras
homolog gene family member C GTPase (RhoC-GTPase)
is overexpressed in 90 % of IBC tumors as compared with
38 % of the stage-matched non-IBC tumors and that in
SUM149 cells overexpression of RhoC-GTPase is associ-
ated with loss of WNT1 inducible signaling pathway 3
(WISP3). Conversely, restoration of WISP3 downregulates
RhoC-GTPase and inhibits the invasive potential of
SUM149 cells [39]. Indeed, RhoC-GTPase is found to play
an essential role in the metastatic behavior of IBC by in-
creasing all aspects of metastatic process, such as cellular
motility and invasion, cytoskeletal assembly, and cell adhe-
sion. RhoC-GTPase controls the cytoskeletal reorganization
by inducing actin stress fiber and focal adhesion contact
formation [40, 41]. While the potential interaction between
IFITM1 and RhoC-GTPase was not directly assessed in
our study, it has been reported that Rho-GTPases can
interact with caveolin 1 (CAV-1) in cancer cells [42]. Not-
ably, IFITM1 has recently been shown to interact with
CAV-1 in colorectal cancer cells, and this interaction im-
pacts the ability of colorectal cancer cells to migrate and
invade [43]. Additionally, IFITM1 has also been shown to
enhance migration and invasion in head and neck cancer
cells through activation of matrix metalloproteinase 12
(MMP12) and MMP13, key enzymes involved in the deg-
radation of the basement membrane that allows cells to
infiltrate into adjacent tissues [15].
IFNα and IFNβ are produced by many cell types, in-
cluding plasmacytoid dendritic cells, lymphocytes, mac-
rophages, and fibroblasts; however, there is evidence that
IFNs can also be produced by tumor cells themselves
[44–46]. Elevated levels of IFN have been reported in
cancer cells as compared with normal primary cells or
normal tissues [18, 47, 48]. Furthermore, increased ex-
pression of some IFN-induced genes has been shown to
be higher in metastatic cancer cells than in nonmeta-
static cells [49]. Our data suggest that IFNα levels are
significantly elevated in IBC cells as compared with non-
IBC cells and that blockade of IFN signaling in these
cells markedly reduces IFITM1 expression. It is critical
to note that IRF3 and IRF7 are the key regulators of type
I IFN production and thus play a central role in innate
immunity [50]. IRF7 regulates the transcription of IFNα/
β genes and ISGs by binding to an ISRE in their pro-
moters via the virus-activated, myeloid differentiation
primary response gene 88 (MyD88)-independent path-
way and the Toll-like receptor-activated, MyD88-
dependent pathway. Notably, we found that IRF7 was
markedly elevated (>2.5-fold) at the mRNA and protein
levels in SUM149 cells compared with SUM190 cells
(data not shown) and that knockdown of IRF7 reduced
IFNα level and blocked its signaling through IFNAR1/2
(Fig. 4a). Furthermore, we found that suppression of
IFNα and IRF7 dramatically reduced IFITM1 expression
in SUM149 cells (Fig. 4b), thus confirming the import-
ance of the IFNα signaling pathway in driving IFITM1
expression in these cells. We should note that while
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endogenous IFNα was elevated in the IBC cells, exogen-
ous addition of IFNα was still able to induce IFITM1,
STAT1, and STAT2 in these cells; however, the further
induction of these ISGs in SUM149 cells did not alter
the growth or aggressive phenotype of these cells.
One of the most prominent findings of our study was
the identification of STAT2 as the critical regulator of
IFITM1 expression in SUM149 cells. The role of STAT2
in canonical JAK-STAT signaling as a part of ISGF3
complex is well documented; however, there is strong
evidence that STAT2 can also homodimerize and com-
bine with IRF9 to form an ISGF3-like complex [51] that
translocates to the nucleus. Once in the nucleus, STAT2
recruits BRG1 to the complex, which then binds to the
ISRE or GAS sequence of IFITM1 promoter and induces
its transcription through noncanonical IFN signaling. It
has been reported that STAT2 complexes, without
STAT1, are capable of inducing a subset of ISGs without
the formation of ISGF3 [52, 53]. For instance, STAT2
was reported to mediate STAT1-independent protection
against dengue virus infection in mice that were defi-
cient in STAT1 through the formation of non-ISGF3
complexes that involved STAT2 homodimers, and did
not require STAT1 [54]. Additionally, Brierley et al. [52, 55]
reported that STAT2 was critical for induction of GAS-
regulated target genes, which was independent of ISGF3.
Our study shows that knockdown of STAT2, but not
STAT1, completely reduced IFITM1 expression and pro-
moter activity in SUM149 cells. We also found that
knockdown of BRG1, the chromatin remodeling protein,
also completely suppressed IFITM1 expression in
SUM149 cells. BRG1 is the ATP subunit of the chromatin
remodeling complex BAF, and studies have shown that
STAT2 and BRG1 interact to induce the expression of cer-
tain ISGs, including IFITM1, through noncanonical IFN
signaling [56, 57]. There is also evidence that the recruit-
ment of BAF to the IFITM1 promoter is mediated in part
by the interaction of BRG1 with STAT2 [58–60]. In our
working model shown in Fig. 9, we propose that overex-
pression of IFITM1 in SUM149 cells is driven by increased
expression of IFNα, which activates the noncanonical type
I IFN signaling pathway where STAT2 homodimers recruit
BRG1 to remodel the promoter and expose ISRE, GAS,
and IRF consensus sequences for the binding of transcrip-
tion factors. This model is supported by a study conducted
by Blaszczyk et al. [51], which showed that IFNα induction
leads to formation of both ISGF3 and STAT2/IRF9 com-
plexes and that the induction of ISGs due to ISGF3 was
rapid and transient, while that due to STAT2/IRF9 was
slow and prolonged, leading to the expression of ISGs long
after the initial induction had ended. Whereas other ISGs
have either the ISRE or the GAS sequences, the IFITM1
promoter region has both the ISRE and GAS sequences as
well as IRF sequences (Additional file 3: Figure S3).
Additionally, STAT2 knockdown in SUM149 cells yielded
results similar to those for IFITM1 knockdown; however,
STAT1 knockdown had little or no effect on the growth or
Fig. 9 Schematic diagram depicting the proposed signaling
pathway involved in interferon-induced transmembrane protein 1
(IFITM1) upregulation in SUM149 cells. IFITM1 is one of the interferon-
stimulated genes (ISGs) that are induced through the canonical Janus
kinase/signal transducer and activator of transcription (JAK-STAT)
pathway due to increased expression of interferon α (IFNα). The binding
of IFNα to its receptor interferon (alpha, beta and omega) receptor
(IFNAR1/2) leads to the induction of the canonical JAK-STAT pathway,
which involves phosphorylation of STAT1, STAT2, and the formation of
the complex interferon-stimulated gene factor 3 (ISGF3), ultimately
inducing many ISGs, including IFITM1. In the nucleus, ISGF3 recruits
chromatin remodeling complex brahma-related gene 1 (BRG1) via
STAT2 to remodel the promoter and expose interferon-stimulated
response element (ISRE)/interferon gamma-activated site (GAS) for
transcription factor binding. Alternatively, STAT2 can homodimerize
upon phosphorylation, and bind interferon regulatory factor 9 (IRF9) to
form a non-ISGF3 complex that is capable of binding the GAS or ISRE/
IRF sequences at the promoter region of a subset of ISGs and induce
their transcription without the participation of STAT1 in a noncanonical
interferon signaling pathway. The presence of both GAS and ISRE/IRF
consensus sequences at the IFITM1 promoter suggests that its
transcription can be induced by both canonical and noncanonical
signaling pathways, resulting in its overexpression in SUM149 cells
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invasive potential of these cells, thus supporting a critical
role for STAT2-BRG1 crosstalk in regulating IFITM1 ex-
pression in these cells.
Conclusions
Our present study reveals a critical role for the IFNα
signaling pathway and IFITM1 overexpression in pro-
moting the aggressive phenotype of the TNIBC cell line
SUM149. The fact that IFITM1 is not expressed in the
HER2-amplified IBC cell lines SUM190 and MDA-IBC-
3 suggests that IFITM1 overexpression might be a unique
marker of aggressiveness in TNIBC. However, further
studies using additional TNIBC cell lines and IBC tumors
are needed to fully assess the prognostic and therapeutic
potential of IFITM1 expression in IBC.
Additional files
Additional file 1: Figure S1. Effects of IFITM1 knockdown on cell cycle
and cell-cycle proteins in SUM149 cells. (PPT 212 kb)
Additional file 2: Figure S2. STAT1 and STAT2 knockdown in SUM149
using three different siRNAs. (PPT 185 kb)
Additional file 3: Figure S3. IFITM1 promoter sequence. (PPT 78 kb)
Abbreviations
ATP: adenosine triphosphate; BAF: brahma-associated factor; BRG1: brahma-
related gene 1; CAV-1: caveolin 1; cDNA: complementary DNA;
CGH: comparative genomic hybridization; DAPI: 4′,6-diamidino-2-
phenylindole; ELISA: enzyme-linked immunosorbent assay; ER: estrogen
receptor; FBS: fetal bovine serum; GAS: interferon gamma-activated site;
HER2: human epidermal growth factor receptor 2; IBC: inflammatory breast
cancer; IFI27: interferon-inducible protein 27; IFIT1: interferon-induced protein
with tetratricopeptide repeats 1; IFITM1: interferon-induced transmembrane
protein 1; IFN: interferon; IFNAR: interferon (alpha, beta and omega) receptor;
IgG: immunoglobulin G; IRF: interferon regulatory factor; ISG: interferon-
stimulated gene; ISGF3: interferon-stimulated gene factor 3; ISRE: interferon-
stimulated response element; JAK: Janus kinase; MMP: matrix metalloproteinase;
mRNA: messenger RNA; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; MyD88: myeloid differentiation primary response gene 88;
PBS: phosphate-buffered saline; PLSCR1: phospholipid scramblase 1;
PUM1: Pumilio RNA-binding family member 1; RhoC-GTPase: Ras homolog
gene family, member C GTPase; RIPA: radioimmunoprecipitation assay;
RLU: Relative Light Units;
RT-PCR: real-time polymerase chain reaction; SD: standard deviation;
SDS: sodium dodecyl sulfate; shRNA: short hairpin RNA; siCon: scrambled
control RNA; siIFN: small interfering interferon; siRNA: small interfering RNA;
STAT: signal transducer and activator of transcription; TBS-T: Tris-buffered
saline and Tween 20; TNIBC: triple-negative inflammatory breast cancer;
WISP3: WNT1 inducible signaling pathway 3.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JLW conceived the study, participated in the research design and
implementation of the study, analyzed and interpreted the data, and drafted
the manuscript. JO performed the experiments, analyzed the data, and
drafted and revised the manuscript. HJC performed some of the
experiments, analyzed some of the data, and assisted in drafting the
manuscript. AL performed and analyzed the ELISA data and revised the
manuscript. MC provided critical reagents for the study and also revised the
manuscript. All authors read and approved the final manuscript.
Authors’ information
JWO, PhD, is a postdoctoral fellow in the Department of Cancer Biology,
University of Kansas Medical Center. HJC, PhD, is a postdoctoral fellow in the
Department of Cancer Biology, University of Kansas Medical Center. AL, MD,
PhD, candidate in the Department of Molecular and Integrative Physiology,
University of Kansas Medical Center. MC, MD, is a professor, in the Division of
Hematology-Oncology, Department of Medicine, Northwestern University
Feinberg School of Medicine. JLW, PhD, is an assistant professor in the
Department of Cancer Biology, University of Kansas Medical Center.
Acknowledgments
This work was supported by grants from the Department of Defense
(W81XWH-12-1-0139; to JLW, HJC, and AL) and the National Cancer Institute
(K01CA120051; to JLW), and by start-up funds from the University of Kansas
Medical Center (to JLW, HJC, JO, and AL). We thank the Flow Cytometry Core
Facility, which is sponsored in part by Centers of Biomedical Research Excellence
(COBRE) grant P30 GM103326 from the National Institute of General Medical
Sciences of the National Institutes of Health, and the University of Kansas
Medical Center Imaging Core for the use of their facilities and equipment.
Plasmid DNA constructs [pGL3-Basic, pGL3-IFITM1 (−750/−1), and pGL3-IFITM1
(−200/−1)] were kindly provided by Dr. Yeon-Su Lee (National Cancer Center,
South Korea).
Author details
1Department of Cancer Biology, University of Kansas Medical Center, Kansas
City, KS, USA. 2Department of Molecular and Integrative Physiology,
University of Kansas Medical Center, Kansas City, KS, USA. 3Department of
Medical Oncology, Northwestern University, Chicago, IL, USA.
Received: 1 June 2015 Accepted: 3 February 2016
References
1. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, et al. Overall
survival differences between patients with inflammatory and
noninflammatory breast cancer presenting with distant metastasis at
diagnosis. Breast Cancer Res Treat. 2015;152(2):407–16.
2. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al.
Inflammatory breast cancer: the disease, the biology, the treatment. CA
Cancer J Clin. 2010;60(6):351–75.
3. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al.
Gene expression profiles of inflammatory breast cancer: correlation with
response to neoadjuvant chemotherapy and metastasis-free survival. Ann
Oncol. 2014;25(2):358–65.
4. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E,
et al. Genomic and expression analysis of microdissected inflammatory
breast cancer. Breast Cancer Res Treat. 2013;138(3):761–72.
5. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo
AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence:
understanding the biology of a unique disease. Cancer.
2007;110(7):1436–44.
6. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, et al.
Essential role for eIF4GI overexpression in the pathogenesis of inflammatory
breast cancer. Nat Cell Biol. 2009;11(7):903–8.
7. Bertucci F, Finetti P, Vermeulen P, Van Dam P, Dirix L, Birnbaum D, et al.
Genomic profiling of inflammatory breast cancer: a review. Breast.
2014;23(5):538–45.
8. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al.
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in
the mouse liver through induction of USP18/UBP43. Mol Cell Biol.
2009;29(17):4841–51.
9. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev
Immunol. 2014;14(1):36–49.
10. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL,
et al. Impaired interferon signaling is a common immune defect in human
cancer. Proc Natl Acad Sci U S A. 2009;106(22):9010–5.
11. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways:
interferon/Stat1 pathway: role in the tumor resistance to genotoxic stress
and aggressive growth. Clin Cancer Res. 2012;18(11):3015–21.
Ogony et al. Breast Cancer Research  (2016) 18:25 Page 17 of 19
12. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via
feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell.
2014;26(2):207–21.
13. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al.
STAT proteins: from normal control of cellular events to tumorigenesis. J
Cell Physiol. 2003;197(2):157–68.
14. Lee J, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, et al. Overexpression of
IFITM1 has clinicopathologic effects on gastric cancer and is regulated by
an epigenetic mechanism. Am J Pathol. 2012;181(1):43–52.
15. He JD, Luo HL, Li J, Feng WT, Chen LB. Influences of the interferon induced
transmembrane protein 1 on the proliferation, invasion, and metastasis
of the colorectal cancer SW480 cell lines. Chin Med J (Engl).
2012;125(3):517–22.
16. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the
antiproliferative action of interferon-γ. Oncogene. 2007;26(4):594–603.
17. Johnson MC, Sangrador-Vegas A, Smith TJ, Cairns MT. Cloning and
characterization of two genes encoding rainbow trout homologues of the
IFITM protein family. Vet Immunol Immunopathol. 2006;110(3-4):357–62.
18. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, et al. IFN-induced
transmembrane protein 1 promotes invasion at early stage of head and neck
cancer progression. Clin Cancer Res. 2008;14(19):6097–105.
19. Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, et al. Knockdown of interferon-
induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration,
and invasion of glioma cells. J Neurooncol. 2011;103(2):187–95.
20. Pan Z, Chen S, Pan X, Wang Z, Han H, Zheng W, et al. Differential gene
expression identified in Uigur women cervical squamous cell carcinoma by
suppression subtractive hybridization. Neoplasma. 2010;57(2):123–8.
21. Gomes AQ, Correia DV, Grosso AR, Lança T, Ferreira C, Lacerda JF, et al.
Identification of a panel of ten cell surface protein antigens associated with
immunotargeting of leukemias and lymphomas by peripheral blood γδ T
cells. Haematologica. 2010;95(8):1397–404.
22. Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, et al.
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory
breast cancer cells. Breast Cancer Res Treat. 2012;134(2):495–510.
23. Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, et al.
Evaluation of candidate stromal epithelial cross-talk genes identifies
association between risk of serous ovarian cancer and TERT, a cancer
susceptibility “hot-spot”. PLoS Genet. 2010;6(7):e1001016.
24. Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA
methyltransferase and histone deacetylase inhibitors induce DNA damage
in small cell lung cancer cells: correlation of resistance with IFN-stimulated
gene expression. Mol Cancer Ther. 2010;9(8):2309–21.
25. Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C, et al. Altered
expression of cell proliferation-related and interferon-stimulated genes in
colon cancer cells resistant to SN38. Cancer Biol Ther. 2008;7(6):822–32.
26. Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon
response genes sensitizes aromatase inhibitor resistant breast cancer cells
to estrogen-induced cell death. Breast Cancer Res. 2015;17:6.
27. Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van
Dam P, Van Marck E, et al. Distinct molecular phenotype of inflammatory
breast cancer compared to non-inflammatory breast cancer using
Affymetrix-based genome-wide gene-expression analysis. Br J Cancer.
2007;97(8):1165–74.
28. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, et
al. Triple-negative subtype predicts poor overall survival and high
locoregional relapse in inflammatory breast cancer. Oncologist.
2011;16(12):1675–83.
29. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, et al. Expression
of growth factor and chemokine receptors: new insights in the biology of
inflammatory breast cancer. Ann Oncol. 2007;18(6):1021–9.
30. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT.
Role of epidermal growth factor receptor in breast cancer. Breast Cancer
Res Treat. 2012;136(2):331–45.
31. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT.
Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin
Oncol. 2009;6(7):387–94.
32. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer
immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.
33. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science (New York,
NY). 2011;331(6024):1565–70.
34. Ferrantini M, Capone I, Marincola FM, Parmiani G, Belardelli F. International
meeting “Immunotherapy of Cancer: Challenges and Needs”. Cancer
Immunol Immunother. 2007;56(4):581–5.
35. Moschos S, Kirkwood JM. Present role and future potential of type I
interferons in adjuvant therapy of high-risk operable melanoma. Cytokine
Growth Factor Rev. 2007;18(5-6):451–8.
36. Buess M, Nuyten DS, Hastie T, Nielsen T, Pesich R, Brown PO.
Characterization of heterotypic interaction effects in vitro to
deconvolute global gene expression profiles in cancer. Genome Biol.
2007;8(9):R191.
37. Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the
tumor microenvironment. Semin Oncol. 2014;41(2):156–73.
38. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al.
STAT1 pathway mediates amplification of metastatic potential and
resistance to therapy. PLoS One. 2009;4(6):e5821.
39. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, et al. WISP3 and RhoC
guanosine triphosphatase cooperate in the development of inflammatory
breast cancer. Breast Cancer Res. 2004;6(1):R110–5.
40. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD.
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype
by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther.
2002;1(8):575–83.
41. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase
overexpression modulates induction of angiogenic factors in breast cells.
Neoplasia (New York, NY). 2000;2(5):418–25.
42. Arpaia E, Blaser H, Quintela-Fandino M, Duncan G, Leong HS, Ablack A, et al.
The interaction between caveolin-1 and Rho-GTPases promotes metastasis
by controlling the expression of alpha5-integrin and the activation of Src.
Ras and Erk Oncogene. 2012;31(7):884–96.
43. Yu F, Xie D, Ng SS, Lum CT, Cai MY, Cheung WK, et al. IFITM1 promotes the
metastasis of human colorectal cancer via CAV-1. Cancer Lett.
2015;368(1):135–43.
44. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon
response and innate immune sensing of cancer. Trends Immunol.
2013;34(2):67–73.
45. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the
tumor microenvironment. Nat Immunol. 2013;14(10):1014–22.
46. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, et al.
Targeting the tumor microenvironment with interferon-beta bridges innate
and adaptive immune responses. Cancer Cell. 2014;25(1):37–48.
47. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al.
Distinctive gene expression patterns in human mammary epithelial cells
and breast cancers. Proc Natl Acad Sci U S A. 1999;96(16):9212–7.
48. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible
protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial
cancers. J Invest Dermatol. 2004;122(3):717–21.
49. Cai D, Cao J, Li Z, Zheng X, Yao Y, Li W, et al. Up-regulation of bone
marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
BMC Cancer. 2009;9:102.
50. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and
function. Genes Immun. 2011;12(6):399–414.
51. Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S,
et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional
response and antiviral activity in the absence of STAT1. Biochem J.
2015;466(3):511–24.
52. Brierley MM, Marchington KL, Jurisica I, Fish EN. Identification of
GAS-dependent interferon-sensitive target genes whose transcription is
STAT2-dependent but ISGF3-independent. FEBS J. 2006;273(7):1569–81.
53. Steen HC, Gamero AM. STAT2 phosphorylation and signaling. JAKSTAT.
2013;2(4):e25790.
54. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S. STAT2 mediates innate
immunity to Dengue virus in the absence of STAT1 via the type I interferon
receptor. PLoS Pathog. 2011;7(2):e1001297.
55. Brierley MM, Fish EN. Functional relevance of the conserved DNA-binding
domain of STAT2. J Biol Chem. 2005;280(13):13029–36.
56. Huang M, Qian F, Hu Y, Ang C, Li Z, Wen Z. Chromatin-remodelling factor
BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat
Cell Biol. 2002;4(10):774–81.
57. Cui K, Tailor P, Liu H, Chen X, Ozato K, Zhao K. The chromatin-remodeling
BAF complex mediates cellular antiviral activities by promoter priming. Mol
Cell Biol. 2004;24(10):4476–86.
Ogony et al. Breast Cancer Research  (2016) 18:25 Page 18 of 19
58. Yan Z, Cui K, Murray DM, Ling C, Xue Y, Gerstein A, et al. PBAF chromatin-
remodeling complex requires a novel specificity subunit, BAF200, to
regulate expression of selective interferon-responsive genes. Genes Dev.
2005;19(14):1662–7.
59. Ni Z, Karaskov E, Yu T, Callaghan SM, Der S, Park DS, et al. Apical role for
BRG1 in cytokine-induced promoter assembly. Proc Natl Acad Sci U S A.
2005;102(41):14611–6.
60. Liu H, Kang H, Liu R, Chen X, Zhao K. Maximal induction of a subset of
interferon target genes requires the chromatin-remodeling activity of the
BAF complex. Mol Cell Biol. 2002;22(18):6471–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ogony et al. Breast Cancer Research  (2016) 18:25 Page 19 of 19
